Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 3, 2007, Pages 202-209

  Ogata, Hiroaki ^a   Koiwa, Fumihiko ^a   Shishido, Kanji ^a   Takahashi, Keiko ^a   Ito, Hidetoshi ^a   Kinugasa, Eriko ^a   Taguchi, Susumu ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Bone metabolic marker; Calcitriol; Secondary hyperparathyroidism; Vitamin D analogue

Indexed keywords

22 OXACALCITRIOL; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; OSTEOCALCIN; PARATHYROID HORMONE; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; OUTCOME ASSESSMENT; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 34248223675     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00422.x     Document Type: Article

References (31)

1. Akizawa T, Shiizaki K, Hatamura I et al. New strategies for the treatment of secondary hyperparathyroidism. Am J Kidney Dis 2003 43 : S100 3.
2. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991 39 : 874 81.
3. Drücke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995 48 : 259 72.
4. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. AM J Physiol Renal Physiol 2002 283 : F367 F76.
5. Ogata H, Koiwa F, Ito H, Kinugasa E. Therapeutic Strategies for Secondary Hyperparathyroidism in Dialysis Patients. Ther Apher Dial 2006 10 : 355 63 in press).
6. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002 17 : 2094 105.
7. Rostand SG, Drücke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999 56 : 383 92.
8. Ganesh SK, Stack AG, Levin NW, Port FK. Association of elevated serum PO4, Ca x P4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001 12 : 2131 8.
9. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 342 : 1478 83.
10. Young EW, Albert JM, Satayathum S et al. Predictors and consequence of altered mineral metabolism: The Dialysis Outcomes and Practice Pattern Study. Kidney Int 2005 67 : 1179 87.
11. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 2004 74 : 2136 43.
12. Goodman WG, Ramirez JA, Belin TA. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994 46 : 1160 6.
13. Hirata M, Endo K, Katsumata K, Ichikawa F, Kubodera N, Fukagawa M. A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 2002 17 (Suppl 10 41 5.
14. Malliche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 2002 62 : 367 74.
15. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989 84 : 728 32.
16. Hirata M, Katsumata K, Misaki T et al. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999 56 : 2040 7.
17. Akizawa T, Suzuki K, Akiba T et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 2002 17 : 28 36.
18. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000 35 : 458 64.
19. Hayashi M, Tsichiya Y, Itaya Y et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicenter trial. Nephrol Dial Transplant 2004 19 : 2067 73.
20. Akizawa T, Ohashi Y, Akiba T et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004 8 : 480 91.
21. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973 4 : 643 6.
22. Koshikawa S, Akizawa T, Kurokawa K et al. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. Nephron 2002 90 : 413 23.
23. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 : S1 S203.
24. Chow S-C, Liu J-P. Design for clinical trials. In : Chow S-C, Liu J-P. Design and Analysis of Clinical Trials: Concepts and Methodologies, New York : John Wiley & Sons, 1998 176 210.
25. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999 55 : 2141 56.
26. Ferreira A, Drücke TB. Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci 2000 320 : 85 9.
27. McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease. Kidney Int 1999 55 : 500 11.
28. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999 33 : 73 81.
29. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 349 : 446 56.
30. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004 19 : 179 84.
31. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005 16 : 1115 25.